Mucinous adenocarcinoma
MONDO:0004957An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.
Also known as: adenocarcinoma, mucinous, malignant, colloid adenocarcinoma, colloid carcinoma, gelatinous adenocarcinoma, gelatinous carcinoma, mucin-producing adenocarcinoma (morphologic abnormality), mucinous adenocarcinoma, mucinous carcinoma
2795 clinical trials for this condition and its sub-types, 18 tagged with Mucinous adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mucinous adenocarcinoma
-
Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types
1 sub-type
- Mucinous adenocarcinoma of the appendix 4 trials · 19 incl. sub-types Sub-types →
-
Ovarian mucinous adenocarcinoma 11 trials · 14 incl. sub-types
1 sub-type
- Ovarian mucinous cystadenocarcinoma 4 trials
-
Mucinous cystadenocarcinoma 1 trial · 5 incl. sub-types
4 sub-types
- Ovarian mucinous cystadenocarcinoma 4 trials
- Appendix mucinous cystadenocarcinoma 0 trials
- Breast mucinous cystadenocarcinoma 0 trials
- Pancreatic mucinous cystadenocarcinoma 0 trials Sub-types →
-
Endometrial mucinous adenocarcinoma 2 trials
-
Mucoepidermoid carcinoma 2 trials
12 sub-types
- Cutaneous mucoepidermoid carcinoma 0 trials
- Extrahepatic bile duct mucoepidermoid carcinoma 0 trials
- Lacrimal gland mucoepidermoid carcinoma 0 trials
- Laryngeal mucoepidermoid carcinoma 0 trials
- Mucoepidermoid breast carcinoma 0 trials
- Mucoepidermoid esophageal carcinoma 0 trials
- Oral cavity mucoepidermoid carcinoma 0 trials Sub-types →
- Paranasal sinus mucoepidermoid carcinoma 0 trials
- Pulmonary mucoepidermoid carcinoma 0 trials Sub-types →
- Thymic mucoepidermoid carcinoma 0 trials
- Thyroid gland mucoepidermoid carcinoma 0 trials
- Trachea mucoepidermoid carcinoma 0 trials
-
Breast mucinous carcinoma 1 trial
1 sub-type
-
Rectum mucinous adenocarcinoma 1 trial
1 sub-type
- Anal mucinous adenocarcinoma 0 trials
-
Cervical mucinous adenocarcinoma 0 trials · 1 incl. sub-types
6 sub-types
- Endocervical type cervical mucinous adenocarcinoma 1 trial
- Cervical mucinous adenocarcinoma, minimal deviation variant 0 trials
- Cervical villoglandular adenocarcinoma 0 trials
- Intestinal variant cervical mucinous adenocarcinoma 0 trials
- Signet ring cell variant cervical mucinous adenocarcinoma 0 trials
- Uterine ligament mucinous adenocarcinoma 0 trials
-
Colloid carcinoma of the pancreas 0 trials
-
3 sub-types
-
Gallbladder mucinous adenocarcinoma 0 trials
-
Lung colloid adenocarcinoma 0 trials
2 sub-types
-
Mucinous gastric adenocarcinoma 0 trials
-
Mucinous pancreas adenocarcinoma 0 trials
Most studied deeper sub-types
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: APL-5125 enters human trials
Disease control OngoingThis study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…
Phase 1/2 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Shorter radiation after breast surgery shows promise for cancer control
Disease control OngoingThis study tests whether a shorter, more focused radiation treatment (accelerated partial breast irradiation) after breast-conserving surgery can effectively control cancer in the breast and nearby lymph nodes for people with early-stage breast cancer. About 537 participants with…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New combo aims to outsmart stubborn colorectal cancer
Disease control OngoingThis phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well…
Phase 2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC